The ACTIVE study protocol: apatinib or placebo plus gefitinib as first-line treatment for patients with EGFR-mutant advanced non-small cell lung cancer (CTONG1706)

Cancer communications (London, England), pp. 692019.

Cited by: 0|Bibtex|Views3|Links
WOS
Keywords:
ApatinibDouble-blindEGFRGefitinibNSCLCMore(5+)

Abstract:

The present study will be the first to evaluate the efficacy and safety profile of the combination of apatinib plus gefitinib as a first-line therapy for patients with EGFR-positive advanced non-squamous NSCLC. Importantly, this trial will provide comprehensive evidence on the treatment of EGFR-TKIs combined with antiangiogenic therapy. T...More

Code:

Data:

Your rating :
0

 

Tags
Comments